|
US4229447A
(en)
|
1979-06-04 |
1980-10-21 |
American Home Products Corporation |
Intraoral methods of using benzodiazepines
|
|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5116817A
(en)
|
1982-12-10 |
1992-05-26 |
Syntex (U.S.A.) Inc. |
LHRH preparations for intranasal administration
|
|
US4596795A
(en)
|
1984-04-25 |
1986-06-24 |
The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services |
Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
|
|
US5011692A
(en)
|
1985-12-28 |
1991-04-30 |
Sumitomo Pharmaceuticals Company, Limited |
Sustained pulsewise release pharmaceutical preparation
|
|
US4755386A
(en)
|
1986-01-22 |
1988-07-05 |
Schering Corporation |
Buccal formulation
|
|
US5739136A
(en)
|
1989-10-17 |
1998-04-14 |
Ellinwood, Jr.; Everett H. |
Intraoral dosing method of administering medicaments
|
|
US5017381A
(en)
|
1990-05-02 |
1991-05-21 |
Alza Corporation |
Multi-unit pulsatile delivery system
|
|
US5229135A
(en)
|
1991-11-22 |
1993-07-20 |
Prographarm Laboratories |
Sustained release diltiazem formulation
|
|
US5523302A
(en)
|
1993-11-24 |
1996-06-04 |
The Du Pont Merck Pharmaceutical Company |
Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
|
|
US20030198640A1
(en)
|
1994-11-07 |
2003-10-23 |
Human Genome Sciences, Inc. |
Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
|
|
US5837284A
(en)
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
|
US5858401A
(en)
|
1996-01-22 |
1999-01-12 |
Sidmak Laboratories, Inc. |
Pharmaceutical composition for cyclosporines
|
|
US6458373B1
(en)
|
1997-01-07 |
2002-10-01 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
|
US5840329A
(en)
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
US20030224400A1
(en)
|
2000-11-17 |
2003-12-04 |
Barber Lauren E. |
Novel human G-protein coupled receptor, HGPRBMY11, and variants thereof
|
|
EP1349928A2
(en)
|
2000-11-17 |
2003-10-08 |
Bristol-Myers Squibb Company |
A novel human g-protein coupled reciptor hgprbmy11 expressed highly in heart and variants thereof
|
|
US7531310B2
(en)
|
2000-11-17 |
2009-05-12 |
Bristol-Myers Squibb Company |
Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11
|
|
SE0004928D0
(sv)
|
2000-12-29 |
2000-12-29 |
Apbiotech Ab |
A method for the manufacturing of porous material
|
|
EP1353937A4
(en)
|
2000-12-29 |
2005-04-13 |
Savient Pharmaceuticals Inc |
SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
|
|
UY27087A1
(es)
|
2001-01-05 |
2002-06-20 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
|
US6960563B2
(en)
|
2001-08-31 |
2005-11-01 |
Morton Grove Pharmaceuticals, Inc. |
Spontaneous emulsions containing cyclosporine
|
|
US11268149B2
(en)
|
2004-12-08 |
2022-03-08 |
Cedars-Sinai Medical Center |
Diagnosis and treatment of inflammatory bowel disease
|
|
US10544459B2
(en)
|
2004-12-08 |
2020-01-28 |
Cedars-Sinai Medical Center |
Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
|
|
US20090317388A1
(en)
|
2005-05-25 |
2009-12-24 |
Linda Burkly |
Tl1a in treatment of disease
|
|
JP5027209B2
(ja)
|
2006-04-07 |
2012-09-19 |
日立化成工業株式会社 |
クローン病患者の末梢血白血球におけるＴ細胞受容体介在性腫瘍壊死因子スーパーファミリー及びケモカインのｍＲＮＡ発現の増強
|
|
US20080085524A1
(en)
|
2006-08-15 |
2008-04-10 |
Prometheus Laboratories Inc. |
Methods for diagnosing irritable bowel syndrome
|
|
WO2008106451A2
(en)
|
2007-02-26 |
2008-09-04 |
Cedars-Sinai Medical Center |
Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
|
|
US20100136543A1
(en)
|
2007-03-02 |
2010-06-03 |
Universite De Liege |
Method for determining the genotype at the crohn's disease locus
|
|
US9305137B1
(en)
|
2007-05-18 |
2016-04-05 |
Cedars-Sinai Medical Center |
Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
|
|
US20150376707A1
(en)
|
2007-05-18 |
2015-12-31 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating inflammatory bowel disease
|
|
WO2009052512A2
(en)
|
2007-10-19 |
2009-04-23 |
Cedars-Sinai Medical Center |
Methods of using genetic variants to diagnose and predict inflammatory bowel disease
|
|
EP2257643B1
(en)
|
2008-02-19 |
2015-04-08 |
The Children's Hospital Of Philadelphia |
Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
|
|
ES2445892T3
(es)
|
2008-08-25 |
2014-03-05 |
Janssen Biotech, Inc. |
Biomarcadores para el tratamiento anti-TNF en colitis ulcerosa y trastornos relacionados
|
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
|
WO2010075579A2
(en)
|
2008-12-24 |
2010-07-01 |
Cedars-Sinai Medical Center |
Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
|
|
NZ619527A
(en)
|
2009-04-14 |
2015-06-26 |
Nestec Sa |
Inflammatory bowel disease prognostics
|
|
WO2011011339A1
(en)
|
2009-07-20 |
2011-01-27 |
Genentech, Inc. |
Gene expression markers for crohn's disease
|
|
US8301232B2
(en)
|
2010-06-08 |
2012-10-30 |
Alivecor, Inc. |
Wireless, ultrasonic personal health monitoring system
|
|
EP2606353A4
(en)
|
2010-08-18 |
2014-10-15 |
Caris Life Sciences Luxembourg Holdings |
CIRCULATING BIOMARKERS FOR DISEASE
|
|
US8766034B2
(en)
|
2010-09-22 |
2014-07-01 |
Cedars-Sinai Medical Center |
TL1A model of inflammation fibrosis and autoimmunity
|
|
SG189391A1
(en)
|
2010-10-18 |
2013-05-31 |
Nestec Sa |
Methods for determining anti-drug antibody isotypes
|
|
JO3375B1
(ar)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
|
US9902996B2
(en)
|
2011-02-11 |
2018-02-27 |
Cedars-Sinai Medical Center |
Methods of predicting the need for surgery in crohn's disease
|
|
MX362132B
(es)
|
2011-05-10 |
2019-01-07 |
Nestec Sa |
Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
|
|
BR112014011491A2
(pt)
|
2011-11-14 |
2017-05-09 |
Nestec Sa |
ensaios e métodos para seleção de um regime de tratamento para um indivíduo com depressão
|
|
JP2016503818A
(ja)
|
2013-01-02 |
2016-02-08 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
Ｔｌ１ａと結合する抗体およびその使用
|
|
JP6671276B2
(ja)
|
2013-03-27 |
2020-03-25 |
セダーズ−シナイ メディカル センター |
Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
|
|
JP6482533B2
(ja)
|
2013-05-17 |
2019-03-13 |
セダーズ−シナイ メディカル センター |
クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
|
|
BR112015029318A2
(pt)
|
2013-05-24 |
2017-07-25 |
Nestec Sa |
marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
|
|
EP4105236A1
(en)
|
2013-07-19 |
2022-12-21 |
Cedars-Sinai Medical Center |
Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
|
|
US10349888B2
(en)
|
2013-10-08 |
2019-07-16 |
Carlos Federico Muniz |
Wearable electroencephalography device and methods of use thereof
|
|
CA2929784C
(en)
*
|
2013-11-13 |
2019-11-26 |
Pfizer Inc. |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
|
WO2022187196A1
(en)
|
2021-03-02 |
2022-09-09 |
Dermtech, Inc. |
Predicting therapeutic response
|
|
WO2015136446A1
(en)
|
2014-03-11 |
2015-09-17 |
Nestec S.A. |
Methods for selecting antidepressant drug therapy to treat depression
|
|
JP7054990B2
(ja)
|
2014-03-27 |
2022-04-15 |
ジェネンテック， インコーポレイテッド |
炎症性腸疾患の診断及び治療のための方法
|
|
US10261098B2
(en)
|
2014-08-18 |
2019-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers for diagnosis and management of neuro-immunological diseases
|
|
WO2016040879A1
(en)
|
2014-09-12 |
2016-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Physical examination method and apparatus
|
|
MX2017004742A
(es)
|
2014-10-20 |
2017-07-20 |
Nestec Sa |
Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
|
|
EP3258837A4
(en)
|
2015-02-20 |
2018-10-10 |
Mc10, Inc. |
Automated detection and configuration of wearable devices based on on-body status, location, and/or orientation
|
|
CA2994719A1
(en)
|
2015-08-21 |
2017-03-02 |
The Children's Hospital Of Philadelphia |
Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
|
|
TWI703158B
(zh)
|
2015-09-18 |
2020-09-01 |
美商希佛隆公司 |
特異性結合tl1a之抗體
|
|
US11266730B2
(en)
|
2015-09-29 |
2022-03-08 |
The General Hospital Corporation |
Methods of treating and diagnosing disease using biomarkers for BCG therapy
|
|
CR20180365A
(es)
*
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
US10732092B2
(en)
|
2015-12-22 |
2020-08-04 |
University Of Maryland, College Park |
Analysis of single cell mechanical phenotyping for metastatic detection
|
|
US11186872B2
(en)
|
2016-03-17 |
2021-11-30 |
Cedars-Sinai Medical Center |
Methods of diagnosing inflammatory bowel disease through RNASET2
|
|
WO2017189846A1
(en)
|
2016-04-27 |
2017-11-02 |
Thaddeus Stappenbeck |
Methods for prognosing crohn's disease comprising human defensin 5 (hd5)
|
|
US10458996B1
(en)
|
2016-05-20 |
2019-10-29 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for determining clinical response to TNF-alpha and/or JAK inhibitors in subjects with inflammatory diseases
|
|
KR20230003433A
(ko)
|
2016-05-20 |
2023-01-05 |
세다르스-신나이 메디칼 센터 |
유전자에 기반한 염증성 장 질환의 진단
|
|
KR20190082815A
(ko)
|
2016-10-26 |
2019-07-10 |
세다르스-신나이 메디칼 센터 |
중화 항-tl1a 단일 클론 항체
|
|
CN117582559A
(zh)
|
2016-12-29 |
2024-02-23 |
泰普治疗公司 |
用于治疗医疗植入物部位的方法和系统
|
|
US20190070166A1
(en)
|
2017-09-02 |
2019-03-07 |
Richard Postrel |
Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease
|
|
US10961581B2
(en)
|
2017-03-22 |
2021-03-30 |
Board Of Regents, The University Of Texas System |
Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in DDX39B (RS2523506) and IL7R (RS6897932)
|
|
US10635787B2
(en)
|
2017-04-19 |
2020-04-28 |
International Business Machines Corporation |
Analysis of output files
|
|
US10626180B2
(en)
|
2017-04-20 |
2020-04-21 |
Cedars-Sinai Medical Center |
Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
|
|
US12105089B2
(en)
|
2017-07-17 |
2024-10-01 |
The Broad Institute, Inc. |
Cell atlas of the healthy and ulcerative colitis human colon
|
|
US20220112625A1
(en)
|
2017-09-02 |
2022-04-14 |
Richard Postrel |
Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses
|
|
WO2019073391A1
(en)
|
2017-10-10 |
2019-04-18 |
Nestec S.A. |
METHODS OF MONITORING VEDOLIZUMAB TREATMENT
|
|
WO2019079647A2
(en)
|
2017-10-18 |
2019-04-25 |
Wuxi Nextcode Genomics Usa, Inc. |
IA STATISTICS FOR DEEP LEARNING AND PROBABILISTIC PROGRAMMING, ADVANCED, IN BIOSCIENCES
|
|
CA3093826A1
(en)
|
2018-03-12 |
2019-09-19 |
Sqz Biotechnologies Company |
Methods for treating hpv-associated diseases
|
|
WO2019186691A1
(ja)
|
2018-03-27 |
2019-10-03 |
日産自動車株式会社 |
自動運転車両の制御方法および制御装置
|
|
US20210079473A1
(en)
|
2018-04-24 |
2021-03-18 |
Cedars-Sinai Medical Center |
Methods and systems for characterizing severe crohn's disease
|
|
CN112585165B8
(zh)
|
2018-04-25 |
2025-02-14 |
普罗米修斯生物科学公司 |
优化的抗tl1a抗体
|
|
TW202014217A
(zh)
|
2018-04-27 |
2020-04-16 |
美國錫安山醫學中心 |
標靶gpr35以治療發炎性腸病症的組合物及方法
|
|
MA52251A
(fr)
|
2018-04-30 |
2021-02-17 |
Cedars Sinai Medical Center |
Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires
|
|
US12264368B2
(en)
|
2018-07-06 |
2025-04-01 |
Cedars-Sinai Medical Center |
Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
|
|
WO2020081186A1
(en)
|
2018-10-15 |
2020-04-23 |
Cedars-Sinai Medical Center |
Methods of treating and diagnosing inflammatory bowel disease
|
|
WO2020082090A1
(en)
|
2018-10-19 |
2020-04-23 |
The Regents Of The University Of Michigan |
Method for monitoring autoimmune disease
|
|
WO2020112890A1
(en)
|
2018-11-29 |
2020-06-04 |
Cedars-Sinai Medical Center |
Rnaset2 compositions and methods of treatment therewith
|
|
CA3121167A1
(en)
|
2018-11-29 |
2020-06-04 |
Cedars-Sinai Medical Center |
Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
|
|
CA3124970A1
(en)
|
2018-12-28 |
2020-07-02 |
Cedars-Sinai Medical Center |
Methods of treating inflammatory bowel diseases that target ripk2
|
|
TWI845600B
(zh)
|
2019-01-24 |
2024-06-21 |
美商普羅米修斯生物科學股份有限公司 |
Gpr35調節劑
|
|
JP2022519819A
(ja)
|
2019-02-08 |
2022-03-25 |
シーダーズ―シナイ メディカル センター |
Ｉｌ１８ｒ１を標的とする炎症性疾患を処置するための方法、システム、およびキット
|
|
CA3128942A1
(en)
|
2019-02-08 |
2020-08-13 |
Cedars-Sinai Medical Center |
Methods, systems, and kits for treating inflammatory disease targeting skap2
|
|
EP3931309A4
(en)
|
2019-02-28 |
2022-12-21 |
SQZ Biotechnologies Company |
ADMINISTRATION OF BIOMOLECULES TO PBMC TO MODIFY AN IMMUNE RESPONSE
|
|
WO2020232125A1
(en)
|
2019-05-14 |
2020-11-19 |
Prometheus Biosciences, Inc. |
Tl1a patient selection methods, systems, and devices
|
|
WO2020242976A1
(en)
|
2019-05-24 |
2020-12-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for diagnosis of polygenic diseases and phenotypes from genetic variation
|
|
US20210018490A1
(en)
|
2019-07-19 |
2021-01-21 |
The Regents Of The University Of Michigan |
Compositions and methods for individualized characterization of non-ige mediated food allergies
|
|
TWI871367B
(zh)
|
2019-10-24 |
2025-02-01 |
美商普羅米修斯生物科學股份有限公司 |
針對類-tnf配體1a(tl1a)之人類化抗體及其用途
|
|
MX2022004942A
(es)
|
2019-10-24 |
2022-07-27 |
Prometheus Biosciences Inc |
Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
|
|
WO2021108694A1
(en)
|
2019-11-27 |
2021-06-03 |
Cedars-Sinai Medical Center |
Predicting extraintestinal manifestations of inflammatory bowel disease
|
|
EP4162076A4
(en)
|
2020-06-03 |
2024-10-02 |
Cedars-Sinai Medical Center |
TREATMENTS FOR A SUBPOPULATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
|
|
WO2021247770A1
(en)
|
2020-06-03 |
2021-12-09 |
Cedars-Sinai Medical Center |
Methods and systems for measuring post-operative disease recurrence
|
|
BR112022025667A2
(pt)
|
2020-06-26 |
2023-03-07 |
Pfizer |
Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
|
|
EP4232146A4
(en)
|
2020-10-22 |
2024-07-31 |
Biora Therapeutics, Inc. |
METHODS OF TREATMENT AND PREDICTION OF NON-RESPONSE TO ANTI-TNF TREATMENT IN PERSONS WITH GASTROINTESTINAL TRACT DISEASES
|
|
EP4232819A4
(en)
|
2020-10-26 |
2024-09-18 |
Technion Research & Development Foundation Limited |
METHODS FOR EVALUATING THE THERAPEUTIC ACTIVITY OF AGENTS FOR THE TREATMENT OF IMMUNE DISEASES
|
|
JP2023551602A
(ja)
|
2020-11-13 |
2023-12-08 |
プロメテウス バイオサイエンシーズ，インク． |
Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
|
|
WO2022119842A1
(en)
|
2020-12-01 |
2022-06-09 |
Cedars-Sinai Medical Center |
Methods and systems of stratifying inflammatory disease patients
|
|
CA3202510A1
(en)
|
2020-12-21 |
2022-06-30 |
Dermot P. Mcgovern |
Tl1a therapy compositions and methods of treatment therewith
|
|
TW202246322A
(zh)
|
2021-02-18 |
2022-12-01 |
美商普羅米修斯生物科學股份有限公司 |
包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
|
|
CA3207818A1
(en)
|
2021-02-18 |
2022-08-25 |
Allison LUO |
Anti-tl1a antibody compositions and methods of treatment in the lung
|
|
WO2022190036A2
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Methods for predicting treatment response in ulcerative colitis
|
|
WO2022232253A1
(en)
|
2021-04-28 |
2022-11-03 |
Cedars-Sinai Medical Center |
Patient selection methods and kits for therapies targeting tl1a
|